An interventional study of Donafenib in Hepatocellular Carcinoma and Adjuvant Therapy, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-03.
Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing donafenib in Carcinoma, Hepatocellular — 9 open to participants now, 9 under way, none of them phase 3. donafenib · Carcinoma, Hepatocellular.
Among the 18 studies testing donafenib in Carcinoma, Hepatocellular, this one has the largest planned enrollment, is one of 7 that started in 2024, is one of 3 with no phase, and was the 14th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →9 of the 18 studies testing donafenib in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:
Haibo Shao · Sites in China
Ages 18–80
Fei Gao · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
Anhui Provincial Hospital · Sites in China
Ages 18–80
Tianjin Medical University Cancer Institute and Hospital
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 4 1
First in 2020; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 204 is above the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 32 across the 18 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 18 have an industry lead sponsor. The 10 most frequent:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 485 studies on the registry; 279 are open to participants now.
16 studies in Carcinoma, Hepatocellular by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: 11 open now, 11 under way, 1 of them phase 3. Of 1 finished, 0 (0%) have results posted.
Among the 16 studies in Carcinoma, Hepatocellular by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2024, is one of 4 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 10th registered.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University’s Carcinoma, Hepatocellular studies by the year they started, since 2013.
3 of the studies testing donafenib in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06498622Anhui Provincial HospitalAdjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab | 2027-05-20 |
| NCT07584018Tianjin Medical University Cancer Institute and HospitalThe DoHAICs Study Expansion Phase | 2027-06-01 |
| NCT06581315Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPostoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma | 2027-08-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies testing donafenib in Carcinoma, Hepatocellular, from their registry updates:
Among Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University’s 16 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Donafenib treatment until disease recurrence or unacceptable toxicity or up to 1 years.
Drug: Donafenib
Active surveillance of participants.
Donafenib 100 mg twice daily (BID)
Also known as: Zepsun
One year recurrence-free survival (RFS) rate
The proportion from randomization to 1 year without recurrence.
Time frame: 1 year
Recurrence-Free Survival (RFS )
The time from randomization to disease recurrence, or death from any cause (whichever occurs first).
Time frame: 6 years
Recurrence-Free Survival rate (RFS rate)
The proportion from randomization to 2 years, 3 years or 5 years without recurrence.
Time frame: 5 years
Overall Survival (OS)
The time from randomization to death from any cause.
Time frame: 6 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2024; primary completion for Aug 2027, 36 months later.
Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 36 months is below that.
Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donafenib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University →